Update on phase i studies in advanced pancreatic adenocarcinoma. hunting in darkness? Highlights from the "2013 ASCO Annual Meeting". Chicago, IL, USA; May 30 - June 4, 2013

Journal of the Pancreas

Volumn 14, Issue 4, 2013, Pages 354-358

  Strimpakos, Alexios S ^a   Wasif Saif, Muhammad ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibodies; Clinical trials; Herbals; Pancreatic neoplasms; Phase I as topic; RNA; Small interfering

Indexed keywords

ARCTIGENIN; CA 19-9 ANTIGEN; ERLOTINIB; FLUOROURACIL; GBS 01; GEMCITABINE; HYALURONIC ACID; IRINOTECAN; OXALIPLATIN; PEGPH 20; RECOMBINANT HYALURONIDASE; SIG12D LODER; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ADVANCED PANCREATIC DUCTAL ADENOCARCINOMA; ARCTIUM LAPPA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CONSENSUS DEVELOPMENT; CONTINUOUS INFUSION; DRUG DEVELOPMENT; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERANCE; ENDOSCOPIC ECHOGRAPHY; FATIGUE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; GENE SILENCING; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; MEDICAL EDUCATION; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; MUSCULOSKELETAL DISEASE; ONCOGENE K RAS; ONCOLOGY; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; SIDE EFFECT; TOXICITY TESTING; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; DEOXYCYTIDINE; FURANS; HUMANS; HYALURONOGLUCOSAMINIDASE; LIGNANS; MUTATION; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECOMBINANT PROTEINS; RNA INTERFERENCE; TREATMENT OUTCOME;

EID: 84880072835     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013 Jan;63(1):11-30. [PMID-23335087]
2. Von Hoff DD, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, et al. Randomized phase III study of weekly nabpaclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT). J Clin Oncol (Meeting Abstracts) 2013 Jan 30;31(4_suppl):LBA148.
3. Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011 May 12;364(19):1817-25. [PMID-21561347]
4. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 Jun;15(6):2403-13. [PMID-9196156]
5. Golan T, Hubert A, Shemi A, Segal A, Dancour A, Khvalevsky EZ, A phase I trial of a local delivery of siRNA against k-ras in combination with chemotherapy for locally advanced pancreatic adenocarcinoma. J Clin Oncol 2013; 31(Suppl.): Abstract #4037.
6. Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008 Sep;27(3):495-522. [PMID-18427734]
7. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, et al. A phase Ib study of gemcitabine plus PEGPH20 (pegylated recombinant human hyaluronidase) in patients with stage IV previously untreated pancreatic cancer. J Clin Oncol 2103; 31(Suppl.): Abstract #4010.
8. Provenzano PP, Hingorani SR. Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. Br J Cancer 2013 Jan 15;108(1):1-8. [PMID-23299539]
9. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013 Jan;62(1):112-20. [PMID-22466618]
10. Ikeda M, Sato A, Mochizuki N, Toyosaki K, Miyoshi C, Fujioka R, et al. A phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine. J Clin Oncol 2103; 31(Suppl.): Abstract #2559.
11. Hayashi K, Narutaki K, Nagaoka Y, Hayashi T, Uesato S. Therapeutic effect of arctiin and arctigenin in immunocompetent and immunocompromised mice infected with influenza A virus. Biol Pharm Bull 2010;33(7):1199-205. [PMID-20606313]
12. Yang S, Ma J, Xiao J, Lv X, Li X, Yang H, et al. Arctigenin antitumor activity in bladder cancer T24 cell line through induction of cell-cycle arrest and apoptosis. Anat Rec (Hoboken) 2012 Aug;295(8):1260-6. [PMID-22619087]